The Miraculous Dostarlimab Cancer Drug is Here!
First time in the history of humanity, a small drug trial conducted on a bunch of people with rectal cancer had their cancer surprisingly go into remission.
According to the New York Times, the experiment was conducted on 18 patients given Dostarlimab, a cancer drug, for about six months. In the end, every patient’s tumor disappeared.
Dostarlimab is a laboratory-produced molecules drug that acts as a substitute for antibodies in the human body. All 18 patients were treated with this drug. As a result, the cancer was completely vanished and even undetectable by physical exams like endoscopy, positron emission tomography or PET scans, and more.
According to Dr. Luis A. Diaz J. of the Memorial Sloan Kettering Cancer Center in New York, “the first time this has happened in the history of cancer.”
Before taking the Dostarlimab cancer drug, the patients were involved in grueling treatments, including chemotherapy, and radiation thearpy, which resulted in bowel, urinary, sexual dysfunction, and many more problems.
The patients were given the drugs and expected to go through these treatments, but no further treatment was needed in reality.
While this news has started making headlines worldwide, Dr. Alan P. Venook, a specialist of colorectal cancer at the University of California, while speaking to a media house, said that the complete suspension of each patient had not been heard of. He also praised the research as a world-first. He even added that it was impressive because none of the patients suffered complications from the Dostarlimab cancer drug.
Additionally, oncologist Dr. Andrea Cercek, Memorial Sloan Kettering Cancer Center, and a co-author of the paper told New York Times, “There were a lot of happy tears” while describing the moment when the patients were cancer-free.
The patients were given a dose of Dostarlimab drug for three weeks in six months for the trial. While all the patients were at the same stages of cancer, it was spreading across the rectum only.
Who Makes Dostarlimab Cancer Drugs?
Developed by a biotech company based in Massachusetts called GlaxoSmithKline. Formerly it was called Tesaro, but it was acquired in 2019. Also, the Dostarlimab is called Jemparli.
Dostarlimab is a monoclonal antibody that was first approved in the US in early 2021 for use in cancer treatment.
What are Monoclonal Antibodies?
As mentioned above, Dostarlimab is a monoclonal antibody, which means these are lab-made antibodies that are genetically modified to fight a specific disease.
However, the term became common in the last two years as several monoclonal antibodies came during the pandemic.
Dostarlimab was developed to fight a certain protein that involved cancer cells called PD1.
During the Memorial Sloan Kettering trial, all the patients’ tumors had a similar mismatch repair deficiency feature.
What is Mismatch Repair Deficiency?
Mismatch repair deficiency is when mutations in cells keep them from fixing mistakes when DNA is copied.
In other words, patients involved in mismatch repair deficiency are likely to develop cancer.
For more health-related information, visit Healthclubfinder.